Michael J Seider1, Stephanie L Pugh2, Corey Langer3, Gwen Wyatt4, William Demas5, Afshin Rashtian6, Cathy L Clausen7, Jerome David Derdel8, Sean F Cleary9, Christopher A Peters10, Ashok Ramalingam11, James E Clarkson12, Michael Tomblyn13, Rachel A Rabinovitch14, Lisa A Kachnic15,16, Lawrence B Berk17. 1. , Cleveland, OH, USA. seider1951@yahoo.com. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA. 3. University of Pennsylvania, Philadelphia, PA, USA. 4. Michigan State University, East Lansing, MI, USA. 5. Salem Regional Medical Center, Salem, OH, USA. 6. University of Southern California-Los Angeles, Los Angeles, CA, USA. 7. St Johns Hospital Cancer Institute, Springfield, IL, USA. 8. Mount Nittany Medical Center Penn State Cancer Institute, State College, PA, USA. 9. Yakima Valley Memorial Hospital, Yakima, WA, USA. 10. Northeast Radiation Oncology Center, Scranton, PA, USA. 11. University Hospitals of Cleveland, Cleveland, OH, USA. 12. Singing River Hospital Regional Cancer Center, Pascagoula, MS, USA. 13. University of South Florida Morsani School of Medicine, Tampa, FL, USA. 14. University of Colorado Denver, Denver, CO, USA. 15. Boston Medical Center MBCCOP, Boston, MA, USA. 16. Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA. 17. Tampa General Hospital, Tampa, FL, USA.
Abstract
BACKGROUND: Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. METHODS: NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153). The primary endpoint was time to development of SREs. Secondary objectives included quality of life (QOL), pain control, overall survival (OS), and toxicity. RESULTS: 261 patients (median age 68; 62% male; 55% prostate, 35% breast, 10% lung) were accrued between July 2006 and February 2011. The study closed early due to a lower than expected rate of SREs. 52 (42%) patients in the ZA arm and 49 (40%) in the radiopharmaceutical arm experienced an SRE. Median time free of SREs was 29.9 and 27.4 months, respectively (p = 0.84). Median OS in the ZA arm and radiopharmaceutical arms was 32.1 and 26.9 months, respectively (p = 0.37). Cox proportional hazards regression model showed that primary disease site (lung) and number of bone metastases (> 2) had a negative impact on OS (p < 0.0001, p = 0.01, respectively). The addition of radiopharmaceuticals to ZA led to a significant reduction in pain at 1 month based on BPI worst score (p = 0.02). No other group differences were noted for QOL or toxicity. CONCLUSION: The addition of radiopharmaceuticals to bisphosphonates did not alter time to SREs or OS for patients with breast, lung, prostate cancers and blastic bone metastases, although it was associated with significant pain reduction at 1 month. CLINICAL TRIAL REGISTRY: This protocol (RTOG 0517) is registered with ClinicalTrials.gov (NCT00365105), and may be viewed online at http://www.clinicaltrials.gov/ct2/show/NCT00365105?term=RTOG+0517&rank=1 .
BACKGROUND: Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. METHODS: NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153). The primary endpoint was time to development of SREs. Secondary objectives included quality of life (QOL), pain control, overall survival (OS), and toxicity. RESULTS: 261 patients (median age 68; 62% male; 55% prostate, 35% breast, 10% lung) were accrued between July 2006 and February 2011. The study closed early due to a lower than expected rate of SREs. 52 (42%) patients in the ZA arm and 49 (40%) in the radiopharmaceutical arm experienced an SRE. Median time free of SREs was 29.9 and 27.4 months, respectively (p = 0.84). Median OS in the ZA arm and radiopharmaceutical arms was 32.1 and 26.9 months, respectively (p = 0.37). Cox proportional hazards regression model showed that primary disease site (lung) and number of bone metastases (> 2) had a negative impact on OS (p < 0.0001, p = 0.01, respectively). The addition of radiopharmaceuticals to ZA led to a significant reduction in pain at 1 month based on BPI worst score (p = 0.02). No other group differences were noted for QOL or toxicity. CONCLUSION: The addition of radiopharmaceuticals to bisphosphonates did not alter time to SREs or OS for patients with breast, lung, prostate cancers and blastic bone metastases, although it was associated with significant pain reduction at 1 month. CLINICAL TRIAL REGISTRY: This protocol (RTOG 0517) is registered with ClinicalTrials.gov (NCT00365105), and may be viewed online at http://www.clinicaltrials.gov/ct2/show/NCT00365105?term=RTOG+0517&rank=1 .
Authors: Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: G O N Oosterhof; J T Roberts; Th M de Reijke; S A Engelholm; S Horenblas; H von der Maase; N Neymark; M Debois; L Collette Journal: Eur Urol Date: 2003-11 Impact factor: 20.096
Authors: Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan Slovin; William K Kelly; Dana Rathkopf; Gretchen A Gignac; David Solit; Lawrence Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph O'Donoghue; Steven Larson; Howard I Scher Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: P M Quilty; D Kirk; J J Bolger; D P Dearnaley; V J Lewington; M D Mason; N S Reed; J M Russell; J Yardley Journal: Radiother Oncol Date: 1994-04 Impact factor: 6.280
Authors: Shi-Ming Tu; Paul Mathew; Franklin C Wong; Donnah Jones; Marcella M Johnson; Christopher J Logothetis Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: Anita J W M Brouns; Ben H De Bie; Marieke H J van den Beuken-van Everdingen; Anne-Marie C Dingemans; Lizza E L Hendriks Journal: Front Oncol Date: 2020-10-22 Impact factor: 6.244
Authors: Clara Martori; Lidia Sanchez-Moral; Tony Paul; Juan Carlos Pardo; Albert Font; Vicenç Ruiz de Porras; Maria-Rosa Sarrias Journal: Cancers (Basel) Date: 2022-01-16 Impact factor: 6.639